-+ 0.00%
-+ 0.00%
-+ 0.00%

China's Apex Court Rules in Novo Nordisk Favor in Semaglutide Patent Case

MT Newswires·12/31/2025 09:00:09
Listen to the news
09:00 AM EST, 12/31/2025 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Wednesday the Supreme People's Court in China upheld the Beijing IP Court's previous ruling that recognized the intellectual property rights for the semaglutide compound patent. Semaglutide, which was invented and developed by the Danish drugmaker, is the main ingredient of the weight loss drug Wegovy. Novo Nordisk noted that the ruling will not affect its previous warning that the expiry of semaglutide's patent in certain countries would have a negative low-single-digit impact on its global sales growth in 2026.